Last 12 months
Inside the activity.
0 purchase rows · 214 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 14 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 26 |
| Apr 2026 | 0 | 14 |
| May 2026 | 0 | 28 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 36 |
| Aug 2026 | 0 | 44 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 6 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 19, 2021 Filed Jul 21, 2021 20:19 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 833 | $64.59 | $53,806.80 |
DisclosureSEC source: 0001447362-21-000176 · wf-form4_162689872837799.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 178,467 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $64.110 to $64.990, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:19 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 833 | $64.59 | $53,806.80 |
DisclosureSEC source: 0001447362-21-000176 · wf-form4_162689872837799.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By DJM Grantor Retained Annuity Trust No. 1 Disclosed balance after: 155,627 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $64.110 to $64.990, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by DJM Grantor Retained Annuity Trust No. 1 of which the Reporting Person is the trustee and beneficiary. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:19 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 570 | $65.11 | $37,112.70 |
DisclosureSEC source: 0001447362-21-000176 · wf-form4_162689872837799.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,018 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $64.985 to $65.290, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 20:19 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 9,430 | $64.59 | $609,055.41 |
DisclosureSEC source: 0001447362-21-000176 · wf-form4_162689872837799.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,588 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $63.970 to $64.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 21:02 UTC |
Goldberg EllenDirector
|
GrantRestricted Stock Units · Derivative | 1,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000174 · wf-form4_162646934375237.xml · derivative · entry 2 Goldberg Ellen · CIK 0001867100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,320 Underlying: Common Stock · 1,320 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on July 14, 2022. F3 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on July 14, 2022. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 21:02 UTC |
Goldberg EllenDirector
|
GrantStock option (right to buy) · Derivative | 5,365 | $0.00 Strike: $66.80 | $0.00 |
DisclosureSEC source: 0001447362-21-000174 · wf-form4_162646934375237.xml · derivative · entry 1 Goldberg Ellen · CIK 0001867100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,365 Underlying: Common Stock · 5,365 shares Expires 2031-07-13 F1 · derivative.exercise_date: One-third of the shares shall vest on July 14, 2022, and the remaining shares shall vest in 24 equal monthly installments thereafter. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 20:58 UTC |
Caple KimDirector
|
GrantRestricted Stock Units · Derivative | 1,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000172 · wf-form4_162646908409583.xml · derivative · entry 2 Caple Kim · CIK 0001867184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,320 Underlying: Common Stock · 1,320 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on July 14, 2022. F3 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on July 14, 2022. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 20:58 UTC |
Caple KimDirector
|
GrantStock option (right to buy) · Derivative | 5,365 | $0.00 Strike: $66.80 | $0.00 |
DisclosureSEC source: 0001447362-21-000172 · wf-form4_162646908409583.xml · derivative · entry 1 Caple Kim · CIK 0001867184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,365 Underlying: Common Stock · 5,365 shares Expires 2031-07-13 F1 · derivative.exercise_date: One-third of the shares shall vest on July 14, 2022, and the remaining shares shall vest in 24 equal monthly installments thereafter. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:16 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 3,100 | $73.44 | $227,676.40 |
DisclosureSEC source: 0001447362-21-000162 · wf-form4_162612096487887.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,018 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $73.170 to $74.090, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:16 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,700 | $72.66 | $341,520.80 |
DisclosureSEC source: 0001447362-21-000162 · wf-form4_162612096487887.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,118 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $72.170 to $73.150, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:16 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,010 | $71.92 | $72,634.15 |
DisclosureSEC source: 0001447362-21-000162 · wf-form4_162612096487887.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,818 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $71.155 to $72.040, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:16 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,190 | $70.40 | $83,774.81 |
DisclosureSEC source: 0001447362-21-000162 · wf-form4_162612096487887.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,828 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $70.010 to $70.940, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,250 | $73.12 | $91,403.75 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 18 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 155,304 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F20 · price: This transaction was executed in multiple trades at prices ranging from $72.910 to $73.270, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 404 | $73.81 | $29,817.62 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 17 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 155,281 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F19 · price: This transaction was executed in multiple trades at prices ranging from $73.580 to $74.050, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 846 | $73.17 | $61,902.67 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 16 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 155,685 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F18 · price: This transaction was executed in multiple trades at prices ranging from $72.580 to $73.520, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 100 | $72.76 | $7,276.00 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 15 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 285,993 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,800 | $72.26 | $130,069.80 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 14 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 286,093 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F17 · price: This transaction was executed in multiple trades at prices ranging from $71.730 to $72.660, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 600 | $70.37 | $42,220.80 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 13 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 287,893 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F16 · price: This transaction was executed in multiple trades at prices ranging from $70.080 to $70.920, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:27 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 700 | $71.01 | $49,706.30 |
DisclosureSEC source: 0001447362-21-000158 · wf-form4_162586243150374.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,018 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $70.960 to $71.040, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:27 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,504 | $70.31 | $316,685.25 |
DisclosureSEC source: 0001447362-21-000158 · wf-form4_162586243150374.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,718 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $69.890 to $70.840, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:27 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,597 | $69.51 | $111,007.47 |
DisclosureSEC source: 0001447362-21-000158 · wf-form4_162586243150374.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,222 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $68.880 to $69.870, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:27 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 2,599 | $68.42 | $177,820.98 |
DisclosureSEC source: 0001447362-21-000158 · wf-form4_162586243150374.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,819 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $67.880 to $68.830, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:27 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 600 | $66.62 | $39,970.80 |
DisclosureSEC source: 0001447362-21-000158 · wf-form4_162586243150374.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,418 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $66.460 to $66.810, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 200 | $71.03 | $14,205.00 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 12 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 156,554 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F15 · price: This transaction was executed in multiple trades at prices ranging from $71.015 to $71.035, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 425 | $70.39 | $29,915.33 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 11 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 156,754 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F14 · price: This transaction was executed in multiple trades at prices ranging from $69.960 to $70.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 202 | $69.23 | $13,984.26 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 10 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 157,179 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F13 · price: This transaction was executed in multiple trades at prices ranging from $68.785 to $69.580, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 223 | $68.26 | $15,221.98 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 9 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 157,381 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F12 · price: This transaction was executed in multiple trades at prices ranging from $67.780 to $68.655, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 200 | $66.75 | $13,349.00 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 157,604 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $66.530 to $66.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 300 | $70.65 | $21,195.60 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 156,531 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $70.555 to $70.730, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 459 | $70.01 | $32,135.51 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 156,831 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F8 · price: This transaction was executed in multiple trades at prices ranging from $69.530 to $70.440, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 391 | $68.64 | $26,839.02 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 157,290 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F7 · price: This transaction was executed in multiple trades at prices ranging from $68.310 to $68.770, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 100 | $66.55 | $6,655.00 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 157,681 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F6 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 360 | $70.89 | $25,520.76 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 288,493 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $70.720 to $71.015, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,440 | $70.07 | $100,903.68 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 288,853 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $69.630 to $70.450, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:13 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 700 | $68.36 | $47,853.40 |
DisclosureSEC source: 0001447362-21-000160 · wf-form4_162612080493305.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 290,293 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted collectively by BioBrit, LLC (the "LLC"), The Annette E. Bradbury Irrevocable Descendants' Trust, and The Daniel M. Bradbury Irrevocable Descendants' Trust on May 26, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.870 to $68.680, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 20:27 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 700 | $71.44 | $50,010.10 |
DisclosureSEC source: 0001447362-21-000158 · wf-form4_162586243150374.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,018 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $71.150 to $71.785, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 20:27 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 3,354 | $70.38 | $236,047.81 |
DisclosureSEC source: 0001447362-21-000158 · wf-form4_162586243150374.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,718 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $70.000 to $70.830, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 20:27 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 5,946 | $69.69 | $414,364.85 |
DisclosureSEC source: 0001447362-21-000158 · wf-form4_162586243150374.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,072 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.990 to $69.960, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 20:08 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 2,100 | $75.45 | $158,445.00 |
DisclosureSEC source: 0001447362-21-000156 · wf-form4_162491091095155.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,018 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $75.15 to $75.92, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 20:08 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 7,900 | $74.79 | $590,841.00 |
DisclosureSEC source: 0001447362-21-000156 · wf-form4_162491091095155.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,118 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.14 to $75.12, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 20:06 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,810 | $75.81 | $137,216.10 |
DisclosureSEC source: 0001447362-21-000154 · wf-form4_162456516664044.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,018 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $75.42 to $76.34, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 23, 2021 Filed Jun 24, 2021 20:06 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 8,190 | $74.90 | $613,431.00 |
DisclosureSEC source: 0001447362-21-000154 · wf-form4_162456516664044.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,828 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $74.42 to $75.40, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:06 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,987 | $74.94 | $373,725.78 |
DisclosureSEC source: 0001447362-21-000154 · wf-form4_162456516664044.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,018 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $74.60 to $75.29, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:06 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 5,013 | $74.18 | $371,864.34 |
DisclosureSEC source: 0001447362-21-000154 · wf-form4_162456516664044.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,005 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $73.60 to $74.59, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 21:36 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 1,273 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-21-000148 · wf-form4_162396576996441.xml · derivative · entry 9 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,137 Underlying: Common Stock · 1,273 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 14, 2021. F5 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 21:36 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 1,273 | $73.00 | $92,929.00 |
DisclosureSEC source: 0001447362-21-000148 · wf-form4_162396576996441.xml · nonDerivative · entry 6 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,920 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 14, 2021. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 21:36 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionCommon Stock | 1,273 | $2.39 | $3,042.47 |
DisclosureSEC source: 0001447362-21-000148 · wf-form4_162396576996441.xml · nonDerivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 14, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 21:47 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 30,000 | $75.07 | $2,252,088.00 |
DisclosureSEC source: 0001447362-21-000152 · wf-form4_162431202430123.xml · nonDerivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 503,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.0453 to $75.0922, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:11 UTC |
Juvenal Tobin WChief Commercial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 4,737 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-21-000150 · wf-form4_162430627131283.xml · derivative · entry 5 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,695 Underlying: Common Stock · 4,737 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2021. F4 · derivative.exercise_date: 25% of the 24,610 shares originally subject to the option vested on May 10, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:11 UTC |
Juvenal Tobin WChief Commercial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 5,263 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001447362-21-000150 · wf-form4_162430627131283.xml · derivative · entry 4 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479 Underlying: Common Stock · 5,263 shares Expires 2027-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2021. F3 · derivative.exercise_date: 25% of the 11,484 shares originally subject to the option vested on July 21, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.